Shield Thereapeutics (#STX) Q1 sales $18m, EVIT $2.5m, cash up at $12.4m
- 2026-05-01 06:59:33
UK 17:01 Tuesday, 27 October 2026
Breaking news and expert analysis on fast-moving AIM and LSE listed shares
Less than five years ago shares in Shield Therapeutics (STX) were 187p and they were a bulletin board darling set to enable numerous gerbils to splash out on new Lamborghinis. Today we bears are vindicated as the shares are just 1.375p but that is still a £10.5 million market cap and I’d be nervous ahead of results next week.
Oh dear, oh dear as disgraced ex share tipster Mike Walters would have said as another of his duff share tips crashed. Did Walters tip Shield Therapeutics (STX) – where I have been a perma-bear – as it sounds like his sort of stock. Today there is news of bogus revenue recognition and a looming cash crisis. What is not to like?
I plead guilty. I recorded the bearcast HERE the other day when I was ill and so marginally delirious so I may have erred when it comes to Shield Therapeutics (STX). Evil Banksta is kind enough to assist me with my maths and he writes:
On 1 August 2022, having failed to raise $30 million in an equity markets fundraise - as I warred here to hoots of derision from BBMs sitting in their underpants in their parent's basement - , Shield Therapeutics (STX) took out a $10 million loan from 13% shareholder AOP Orphan International AG. Now the clock is ticking on that loan.
Greg Madison was appointed as CEO of Shield Therapeutics (STX) on June 1 2021. The shares were then 60p. Today they are 8p. In just over a year Greg has presided over a catastrophic 87% destruction of shareholder value. Luckily Greg had no shares himself just a stack of options granted to him two weeks after he joined, to incentivise him.
The first cut is the least painful. That is to say, selling when it is clear a company is fecked, is less painful than waiting to sell in such circumstances. The document today published by Shield (STX) shows just how fecked it is.
Oh dear, oh dear. This is truly awful, and explains why results normally released in late April, came out today - deadline day. Shield Therapeutics (STX) is in a mess, as I warned so often. Ouzo for me. Cabbage water for those who ignored my explicit warnings and instead, hurled abuse at me.
On February 18, I generated industrial-scale abuse (of me) from anonymous internet warriors. All I did was suggest Shield Therapeutics (STX) as a slam-dunk short, at 25.5p. The savants insisted, as is usually the case in such circumstances, that I didn’t understand the maths, and should go back to working in a pizza store, etc, etc, etc. The shares are now just 14.6p, and the final collapse is almost upon us. Add to your shorts. Let me explain.
When I suggested Shield Therapeutics (STX) was a nailed-down short, on the basis that it would face a cash crisis by May, my analysis was met with derision by Bulletin Board Morons. “He does not understand biotech, he does not understand Shield, he’s a failed fund manager, he is ALWAYS wrong, he works in a pizza store, he’s fleeing the UK to Greece to avoid jail”, were some of the more polite comments. It is now May, and the shares are just 17p to sell. So, what next?
Shield Therapeutics (STX) has the status Omega Diagnostics (ODX) once had as a darling of the Bulletin Board savants. And like Omega was this company is heading for a cash crisis and its shares will tank by 80%. Though this will enrage a shareholder base with the collective IQ of a cheese sandwich, the shares are a stand out short at 25.5p with a 5.5p target. Chaps and gals ,before you start the hate attacks on me learn from the Omega debacle HERE. Now as to why Shield shares will collapse, here’s why.
Hello, Share Trappers. You may recall my weekend ramblings when I suggested that supporting some medical pioneers might be worth considering. One reason is that rewards, when they come, are spectacular. Though it must be observed in the same breath that setbacks can be catastrophic. Just like mining shares, the failures seem to come faster than the successes. So anyone who doesn't like too much risk should look away now...
